Приложение временно недоступно
Vivanos Health
Разработчик:
Vivanos Health
Описание
Diabetes management app designed for use by Primary Care Providers for their patients.
Disclaimer
The use of this app is for informational purposes only and should not and cannot serve as a substitute for an examination and treatment by a qualified health care provider. Each person’s condition and situation is unique and individuals should consult a qualified health care provider for medical advice and answers to personal health questions. While this app attempts to be as accurate as possible, it should not be relied upon as being comprehensive or error-free.
Citations
Standards of Medical Care in Diabetes: Summary of Revisions.
DIABETES CARE 2022;45
https://diabetesjournals.org/care/article/45/Supplement_1/S4/138912/Summary-of-Revisions-Standards-of-Medical-Care-in
The Effect of Intensive Blood Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34).
LANCET 1998;352:854.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)07037-8/fulltext
Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes (UKPDS 39).
BR MED J 1998; 317:713.
https://pubmed.ncbi.nlm.nih.gov/9732338/
Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49).
JAMA 1999: 281:2005.
https://jamanetwork.com/journals/jama/fullarticle/190204
Intensive Blood Glucose Control with Sulfonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33).
Lancet 1998; 352:837.
https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(98)07019-6.pdf
Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes (UKPDS 38).
BMJ 1998; 317:703.
https://pubmed.ncbi.nlm.nih.gov/9732337/
DCCT Research Group: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus.
N ENGL J MED 1993; 329:977.
https://www.nejm.org/doi/full/10.1056/nejm199309303291401
Скрыть
Показать больше...
Disclaimer
The use of this app is for informational purposes only and should not and cannot serve as a substitute for an examination and treatment by a qualified health care provider. Each person’s condition and situation is unique and individuals should consult a qualified health care provider for medical advice and answers to personal health questions. While this app attempts to be as accurate as possible, it should not be relied upon as being comprehensive or error-free.
Citations
Standards of Medical Care in Diabetes: Summary of Revisions.
DIABETES CARE 2022;45
https://diabetesjournals.org/care/article/45/Supplement_1/S4/138912/Summary-of-Revisions-Standards-of-Medical-Care-in
The Effect of Intensive Blood Glucose Control with Metformin on Complications in Overweight Patients with Type 2 Diabetes (UKPDS 34).
LANCET 1998;352:854.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)07037-8/fulltext
Efficacy of Atenolol and Captopril in Reducing Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes (UKPDS 39).
BR MED J 1998; 317:713.
https://pubmed.ncbi.nlm.nih.gov/9732338/
Glycemic Control with Diet, Sulfonylurea, Metformin, or Insulin in Patients with Type 2 Diabetes Mellitus: Progressive Requirement for Multiple Therapies (UKPDS 49).
JAMA 1999: 281:2005.
https://jamanetwork.com/journals/jama/fullarticle/190204
Intensive Blood Glucose Control with Sulfonylureas or Insulin Compared with Conventional Treatment and Risk of Complications in Patients with Type 2 Diabetes (UKPDS 33).
Lancet 1998; 352:837.
https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(98)07019-6.pdf
Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes (UKPDS 38).
BMJ 1998; 317:703.
https://pubmed.ncbi.nlm.nih.gov/9732337/
DCCT Research Group: The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus.
N ENGL J MED 1993; 329:977.
https://www.nejm.org/doi/full/10.1056/nejm199309303291401
Скриншоты
Vivanos Health Частые Вопросы
-
Приложение Vivanos Health бесплатное?
Да, Vivanos Health полностью бесплатное и не содержит встроенных покупок или подписок.
-
Является ли Vivanos Health фейковым или мошенническим?
Недостаточно отзывов для надежной оценки. Приложению нужно больше отзывов пользователей.
Спасибо за ваш голос -
Сколько стоит Vivanos Health?
Приложение Vivanos Health бесплатное.
-
Сколько зарабатывает Vivanos Health?
Чтобы получить оценку дохода приложения Vivanos Health и другие данные AppStore, вы можете зарегистрироваться на платформе мобильной аналитики AppTail.
Оценки пользователей
Приложение еще не оценено в Египет.
История оценок
Vivanos Health Отзывы Пользователей
Vivanos Health Установки
30дн.
Vivanos Health Доход
30дн.Vivanos Health Доходы и Загрузки
Получите ценные инсайты о производительности Vivanos Health с помощью нашей аналитики.
Зарегистрируйтесь сейчас, чтобы получить доступ к статистика загрузок и доходов и многому другому.
Зарегистрируйтесь сейчас, чтобы получить доступ к статистика загрузок и доходов и многому другому.
Информация о приложении
- Категория
- Medical
- Разработчик
- Vivanos Health
- Языки
- English
- Последнее обновление
- 1.1.11 (2 месяца назад )
- Выпущено
- Dec 19, 2022 (2 года назад )
- Также доступно в
- ОАЭ , Египет , Испания , Франция , Республика Корея , Новая Зеландия , Португалия , Сингапур , Таиланд , Соединенные Штаты
- Обновлено
- 6 месяцев назад
This page includes copyrighted content from third parties, shared solely for commentary and research in accordance with fair use under applicable copyright laws. All trademarks, including product, service, and company names or logos, remain the property of their respective owners. Their use here falls under nominative fair use as outlined by trademark laws and does not suggest any affiliation with or endorsement by the trademark holders.
AppTail.